Mancia Giuseppe, Grassi Guido, Zanchetti Alberto
Clinica Medica, Dipartimento di Medicina Clinica, Prevenzione e Biotecnologie Sanitarie, Università Milano, Bicocca, Italy. giuesppe,
J Hypertens. 2006 Jan;24(1):3-10. doi: 10.1097/01.hjh.0000194119.42722.21.
Observational studies have provided evidence that a consistent fraction (approximately 15-20%) of hypertensive patients displays a glucose intolerance state that may be aggravated by antihypertensive drug regimens based on thiazide diuretics or beta-blockers. This review examines the relative and absolute diabetogenic effects of antihypertensive drugs, by comparing the impact of 'new' (calcium antagonists, angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists) versus 'old' (diuretics and beta-blockers) drugs on new-onset diabetes in recent clinical trials. Evidence is provided that compared with diuretics and beta-blockers, new-onset diabetes is less common with 'new' drugs, and that conventional antihypertensive compounds, particularly when combined together, may amplify the natural time-dependent tendency towards the development of this metabolic disease. This paper provides new insights into the potential mechanisms responsible for the phenomenon and the clinical significance of antihypertensive drug-induced diabetes.
观察性研究已提供证据表明,持续有一部分(约15%-20%)高血压患者存在葡萄糖不耐受状态,而基于噻嗪类利尿剂或β受体阻滞剂的降压药物治疗方案可能会加重这种状态。本综述通过比较近期临床试验中“新型”(钙拮抗剂、血管紧张素转换酶抑制剂和血管紧张素II受体拮抗剂)与“传统”(利尿剂和β受体阻滞剂)药物对新发糖尿病的影响,研究了降压药物相对和绝对的致糖尿病作用。有证据表明,与利尿剂和β受体阻滞剂相比,“新型”药物导致的新发糖尿病较少见,而且传统降压药物联合使用时,可能会放大这种代谢疾病自然随时间发展的倾向。本文对降压药物诱发糖尿病这一现象的潜在机制及临床意义提供了新的见解。